|
|
 | ||
 Myocardial Infarction Reperfusion Injury | ||
 |
Myocardial infarction (heart attack) is one of the most common causes of sudden death in patients with coronary heart disease (CHD). Acute myocardial infarction is the main killer of sudden death. Nearly ten million people die of sudden myocardial infarction every year in the world, and nearly one million people die every year in China. The patients with myocardial infarction treated by thrombolysis or coronary stenting may face reperfusion injury. |
|
Myocardial Reperfusion Injury | ||
 | ||
| ||
|
Myocardial reperfusion injury is the secondary myocardial injury after thrombolysis or coronary stenting in hospital patients with myocardial infarction. It is the main cause of ventricular aneurysm and heart failure. Although myocardial ischemia/reperfusion injury has been known for nearly 40 years, there is still a lack of effective prevention/treatment for myocardial reperfusion injury. Therefore, after myocardial infarction blood flow reconstruction, many patients suffer from heart failure and readmission, which seriously affects the quality of life of these patients. Our innovative product AMZ003 effectively reduces the infarct size (70%) caused by myocardial ischemia/reperfusion in rats, inhibits the malignant arrhythmia caused by myocardial reperfusion, and may fill the clinical gap of lacking protective drugs against myocardial reperfusion injury. |
|